February’s program was held at The Yale Club. To download the event flyer, click here.
Panel 1: Diverse Tracks to the Global Market: Journey of Chinese, Japanese and Korean Pharma (1:15 – 2:15 PM)
Mark Paxton, JD, Executive Vice President, W Medical Strategy Group (moderator)
Howard Kim, Director of Business Development, Yonsung Fine Chemicals
Joy Wang, PhD, MBA, US Office Head of Simcere Pharmaceuticals
Mark Dennish, Vice President, Business Development and New Product Planning, Daiichi Sankyo Inc.
Panel 2: Fitting into the Ecosystem: New Sustainable Strategies of Collaboration (2:15 – 3:15 PM)
Kimberly Ha, Senior Director, FTI Consulting (moderator)
Bryan Spielman, Executive Vice President, Medidata
Debra Yu, MD, Managing Director of Labrador Advisors
Les Funtleyder, Director of Strategic Investments, OPKO Health
Panel 3: Expansion Strategies of East Asian Pharma Companies: Shifting the Paradigm (3:15 – 4:15 PM)
Joe McMenamin, MD, JD, EVP, W Medical Strategy Group (moderator)
Han Choi, MD, LLM, Principal, Oracle Investment
Young-Seok Byun, PhD, Head of R&D, UK ChemiPharm
Yuan-Hua Ding, PhD, Executive Director & Head, Asia/Pacific, Pfizer
On February 11th, New York Pharma Forum and the New York Health Forum will jointly sponsor a program highlighting business growth and globalization strategies of biopharma companies from China, Korea and Japan, and trends in U.S. biopharma business development and business collaboration with East Asian biopharma companies.
The New York Health Forum was founded with the aim of providing a communication channel for the U.S.-Korea biopharmaceutical and healthcare industry. A major mission of the New York Health Forum is to provide a foundation for communication among all areas of biomedicine and the healthcare industry, resulting in solutions which combine the ideas of science, industry, and policy initiatives for a healthier society. Its quarterly meetings, attended mostly by Korean pharma and related health industry executives, are organized by W Medical Strategy Group, founded by DoHyun Cho, Ph.D., who previously served as the Korean government’s biopharmaceutical liaison for the U.S.
This meeting is a good opportunity for NYPF members, who are already familiar with U.S.-Japan pharma industry business strategies, to learn more about the status and business strategies of Korean and Chinese companies and to network with a mixed audience of American, Korean, Japanese and Chinese biopharma and health industry executives.